Xeraya Capital-backed InterVenn Biosciences raises $34m in Series B round

Xeraya Capital-backed InterVenn Biosciences raises $34m in Series B round

US-based InterVenn Biosciences, a portfolio company of Malaysia private equity and venture capital firm Xeraya Capital, has raised $34 million in an oversubscribed Series B funding.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter